← Tillbaka till ranking

BioArctic B

BIOA-B.ST OMXS Healthcare
AVVAKTA
53/100
Rank 52 av 289
327.40 SEK -2.27% idag

Kursutveckling (180 dagar)

BIOA-B.ST OMX30 (normaliserad)

Kursutveckling vs OMX30

1 dag
-2.27%
-0.9% vs OMX30
1 vecka
+3.22%
+0.6% vs OMX30
1 månad
+12.90%
+16.7% vs OMX30
3 månader
+4.47%
+0.9% vs OMX30
6 månader
+13.13%
+1.0% vs OMX30

Fundamentala nyckeltal

28.4
112.9
14.8
14.5
+81.8%
51.1%
18.1%
71.4%
46.9%
2%
4.78
29.0B
NONE Riktkurs: 304 SEK (5 analytiker)

AI-analys

8.8
0.0
53.1
MEDEL

Kort sikt (3 månader)

54/100

Baserat enbart på tekniska signaler.

Lång sikt (3 år)

52/100

Baserat enbart på sentiment, inga fundamenta tillgängliga.

Fallback: teknisk=9, sentiment=0. AI-analys ej tillgänglig.

  • AI-analys misslyckades

Senaste nyheter

yahoo_finance 2026-03-08
BioArctic (OM:BIOA B) Valuation Check After Recent Share Price Weakness And Leqembi Growth Expectations

Why BioArctic Is On Investors’ Radar Today BioArctic (OM:BIOA B) has been drawing attention after recent share performance and fresh financial figures, prompting investors to reassess how its central ...

yahoo_finance 2026-02-18
BioArctic AB (BRCTF) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Partnerships ...

BioArctic AB (BRCTF) reports a transformative year with significant financial growth, new project expansions, and successful global partnerships, despite challenges in European markets.

yahoo_finance 2026-01-27
Assessing BioArctic (OM:BIOA B) Valuation After Recent Share Price Momentum

Why BioArctic is on investors’ radar today BioArctic (OM:BIOA B) has recently drawn attention without a clear single news catalyst, as investors focus on its central nervous system drug pipeline, coll...

yahoo_finance 2025-12-05
How Leqembi’s Subcutaneous “Time Savings” Data Could Impact Eisai (TSE:4523) Investors

Eisai and partner BioArctic recently reported at the CTAD 2025 conference that long-term data for Leqembi (lecanemab) suggest early, continued treatment can substantially delay progression from mild c...

yahoo_finance 2025-11-14
Why BioArctic (OM:BIOA B) Is Up 6.3% After Leqembi Royalties and Novartis Partnership Boost Sales

BioArctic AB reported its third quarter 2025 results, highlighting SEK133.35 million in sales compared to SEK76.63 million a year earlier, alongside a net loss of SEK86.87 million due to increased R&D...